|
1
|
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
|
JAMA
|
2011
|
11.02
|
|
2
|
Intermittent androgen suppression for rising PSA level after radiotherapy.
|
N Engl J Med
|
2012
|
8.64
|
|
3
|
A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.
|
Eur Urol
|
2010
|
7.70
|
|
4
|
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.
|
J Clin Oncol
|
2011
|
3.59
|
|
5
|
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group.
|
Eur Urol
|
2013
|
3.34
|
|
6
|
Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review.
|
Eur Urol
|
2012
|
3.30
|
|
7
|
Active surveillance for prostate cancer: progress and promise.
|
J Clin Oncol
|
2011
|
2.93
|
|
8
|
A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.
|
Eur Urol
|
2006
|
2.80
|
|
9
|
Prostate cancer screening: Canadian guidelines 2011.
|
Can Urol Assoc J
|
2011
|
2.50
|
|
10
|
Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
|
J Urol
|
2002
|
2.11
|
|
11
|
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer.
|
J Urol
|
2008
|
1.95
|
|
12
|
Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients.
|
J Clin Endocrinol Metab
|
2013
|
1.81
|
|
13
|
Critical evaluation of hormonal therapy for carcinoma of the prostate.
|
Urology
|
2002
|
1.67
|
|
14
|
Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
|
Cancer
|
2007
|
1.66
|
|
15
|
Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study.
|
J Urol
|
2012
|
1.47
|
|
16
|
Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?
|
Int J Radiat Oncol Biol Phys
|
2002
|
1.45
|
|
17
|
Active surveillance for prostate cancer.
|
JAMA
|
2010
|
1.44
|
|
18
|
Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
|
Int J Urol
|
2012
|
1.34
|
|
19
|
Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men.
|
J Natl Cancer Inst
|
2013
|
1.32
|
|
20
|
A prospective comparison of MRI-US fused targeted biopsy versus systematic ultrasound-guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance.
|
J Magn Reson Imaging
|
2014
|
1.21
|
|
21
|
Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance.
|
Eur Urol
|
2011
|
1.20
|
|
22
|
The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation.
|
Arch Pathol Lab Med
|
2014
|
1.17
|
|
23
|
Modeling prostate specific antigen kinetics in patients on active surveillance.
|
J Urol
|
2006
|
1.15
|
|
24
|
Re: editorial comment on focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study (lancet oncol 2012; 13: 622-632).
|
J Urol
|
2012
|
1.15
|
|
25
|
Active surveillance, quality of life, and cancer-related anxiety.
|
Eur Urol
|
2013
|
1.14
|
|
26
|
Role of "saturation biopsy" in the detection of prostate cancer among difficult diagnostic cases.
|
Urology
|
2002
|
1.14
|
|
27
|
Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer.
|
J Urol
|
2010
|
1.13
|
|
28
|
MR imaging-controlled transurethral ultrasound therapy for conformal treatment of prostate tissue: initial feasibility in humans.
|
Radiology
|
2012
|
1.13
|
|
29
|
Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer.
|
Clin Genitourin Cancer
|
2008
|
1.12
|
|
30
|
MRI-guided transurethral ultrasound therapy of the prostate gland using real-time thermal mapping: initial studies.
|
Urology
|
2010
|
1.12
|
|
31
|
Dietary fat and prostate cancer.
|
J Urol
|
2004
|
1.10
|
|
32
|
Analysis of the spatial and temporal accuracy of heating in the prostate gland using transurethral ultrasound therapy and active MR temperature feedback.
|
Phys Med Biol
|
2009
|
1.07
|
|
33
|
Active surveillance for low-risk prostate cancer: an update.
|
Nat Rev Urol
|
2011
|
1.05
|
|
34
|
Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
|
J Urol
|
2010
|
1.03
|
|
35
|
Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix.
|
J Urol
|
2011
|
1.00
|
|
36
|
Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experience.
|
Urology
|
2002
|
1.00
|
|
37
|
Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters.
|
Cancer
|
2006
|
0.98
|
|
38
|
Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature.
|
Eur Urol
|
2012
|
0.98
|
|
39
|
Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance.
|
J Urol
|
2010
|
0.95
|
|
40
|
Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet.
|
Biochem Biophys Res Commun
|
2010
|
0.95
|
|
41
|
Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer.
|
J Urol
|
2011
|
0.93
|
|
42
|
MR thermometry in the human prostate gland at 3.0T for transurethral ultrasound therapy.
|
J Magn Reson Imaging
|
2013
|
0.93
|
|
43
|
Analytical accuracy and reliability of commonly used nutritional supplements in prostate disease.
|
J Urol
|
2002
|
0.90
|
|
44
|
The burden of prostate cancer in Canada.
|
Can Urol Assoc J
|
2009
|
0.90
|
|
45
|
Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.
|
BJU Int
|
2011
|
0.90
|
|
46
|
Antiproliferative mechanisms of the flavonoids 2,2'-dihydroxychalcone and fisetin in human prostate cancer cells.
|
Nutr Cancer
|
2010
|
0.89
|
|
47
|
Comment on the US Preventive Services Task Force's draft recommendation on screening for prostate cancer.
|
Eur Urol
|
2012
|
0.87
|
|
48
|
Age-related properties of the tumour vasculature in renal cell carcinoma.
|
BJU Int
|
2010
|
0.86
|
|
49
|
Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.
|
Urology
|
2002
|
0.86
|
|
50
|
Urothelial carcinoma of the prostate.
|
Urology
|
2007
|
0.86
|
|
51
|
Cardiovascular effects of androgen depletion and replacement therapy.
|
Urology
|
2006
|
0.85
|
|
52
|
Soy consumption and phytoestrogens: effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlipidemic men.
|
J Urol
|
2003
|
0.83
|
|
53
|
Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation.
|
Clin Biochem
|
2002
|
0.83
|
|
54
|
Prostate cancer immunology - an update for Urologists.
|
BJU Int
|
2010
|
0.83
|
|
55
|
Active surveillance for prostate cancer: the role of the pathologist.
|
Pathology
|
2015
|
0.82
|
|
56
|
Early prostate cancer--treat or watch?
|
N Engl J Med
|
2011
|
0.81
|
|
57
|
Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist.
|
Virchows Arch
|
2014
|
0.81
|
|
58
|
Clinical trial risk in castration-resistant prostate cancer: immunotherapies show promise.
|
BJU Int
|
2013
|
0.80
|
|
59
|
A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studies.
|
Radiother Oncol
|
2008
|
0.80
|
|
60
|
Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma.
|
BJU Int
|
2004
|
0.80
|
|
61
|
Induction of specific human cytotoxic T cells using dendritic cells transduced with an adenovector encoding rat epidermal growth factor receptor 2.
|
Int J Oncol
|
2011
|
0.79
|
|
62
|
Variation in patterns of practice in diagnosing screen-detected prostate cancer.
|
BJU Int
|
2004
|
0.79
|
|
63
|
Conservative versus radical therapy of prostate cancer: how have recent advances in molecular markers and imaging enhanced our ability to prognosticate risk?
|
Semin Oncol
|
2003
|
0.79
|
|
64
|
Strengthening evidence for active surveillance for prostate cancer.
|
Eur Urol
|
2012
|
0.79
|
|
65
|
Active surveillance for favorable-risk prostate cancer: a short review.
|
Korean J Urol
|
2010
|
0.78
|
|
66
|
Novel approaches to improve prostate cancer diagnosis and management in early-stage disease.
|
BJU Int
|
2012
|
0.78
|
|
67
|
The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer.
|
Urol Oncol
|
2008
|
0.78
|
|
68
|
Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers.
|
World J Urol
|
2015
|
0.77
|
|
69
|
Management of low- and intermediate-risk prostate cancer.
|
World J Urol
|
2015
|
0.77
|
|
70
|
Intermittent androgen suppression in prostate cancer: the Canadian experience.
|
Urology
|
2002
|
0.76
|
|
71
|
What can surrogate tissues tell us about the oxidative stress status of the prostate? A hypothesis-generating in-vivo study.
|
PLoS One
|
2010
|
0.76
|
|
72
|
Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists.
|
Can Urol Assoc J
|
2009
|
0.76
|
|
73
|
Advances in the management of high-risk localised and metastatic prostate cancer.
|
BJU Int
|
2012
|
0.76
|
|
74
|
Prostate cancer: intermittent ADT--tales from a 27-year odyssey.
|
Nat Rev Urol
|
2013
|
0.75
|
|
75
|
Re: Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis: D. Liu, H. P. Lehmann, K. D. Frick and H. B. Carter. J Urol 2012; 187: 1241-1246.
|
J Urol
|
2012
|
0.75
|
|
76
|
Balancing potential quality-of-life benefits against the risk of lethal late recurrence with bladder-preserving surgery.
|
Curr Oncol
|
2010
|
0.75
|
|
77
|
Realistic anatomical prostate models for surgical skills workshops using ballistic gelatin for nerve-sparing radical prostatectomy and fruit for simple prostatectomy.
|
Korean J Urol
|
2011
|
0.75
|
|
78
|
Feasibility and safety of silicone rubber contrast-enhanced microcomputed tomography in evaluating the angioarchitecture of prostatectomy specimens.
|
Transl Oncol
|
2011
|
0.75
|
|
79
|
Dutasteride and prostate cancer.
|
N Engl J Med
|
2010
|
0.75
|
|
80
|
Re: Delay of surgery in men with low risk prostate cancer: D. O'Brien, S. Loeb, G. F. Carvalhal, B. B. McGuire, D. Kan, M. D. Hofer, J. T. Casey, B. T. Helf and W. J. Catalona. J Urol 2011; 185: 2143-2147.
|
J Urol
|
2011
|
0.75
|
|
81
|
Response to the article by J.E. Montie, Screen detected, low volume prostate cancer: the case for active treatment. Urol Oncol 2008;26:511-515.
|
Urol Oncol
|
2009
|
0.75
|
|
82
|
Outcomes of treatment vs observation of localized prostate cancer in elderly men.
|
JAMA
|
2007
|
0.75
|
|
83
|
Clinical significance of biopsy-derived primary Gleason score among radical prostatectomy candidates with Gleason 7 tumors.
|
Urology
|
2002
|
0.75
|
|
84
|
Re: A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. T. Wolters, M. J. Roobol, P. J. van Leeuwen, R. C. van den Bergh, R. F. Hoedemaeker, G. J. van Leenders, F. H. Schröder and T. H. van der Kwast. J Urol 2011;185: 121-125.
|
J Urol
|
2011
|
0.75
|
|
85
|
Focal therapy: definition and rationale.
|
Curr Opin Urol
|
2022
|
0.75
|
|
86
|
An interview with Laurence Klotz, MD, FRCSC. Interview by John Fitzpatrick.
|
BJU Int
|
2011
|
0.75
|
|
87
|
Personalized cancer therapy for urological cancers: from bench to bedside and back.
|
Adv Urol
|
2012
|
0.75
|
|
88
|
[Reevaluation of MAB therapy and progress of endocrine therapy].
|
Gan To Kagaku Ryoho
|
2005
|
0.75
|
|
89
|
Publishing in Urology: My 20-year journey.
|
Can Urol Assoc J
|
2012
|
0.75
|
|
90
|
Active Surveillance for Prostate Cancer: How to Do It Right.
|
Oncology (Williston Park)
|
2017
|
0.75
|
|
91
|
Laurence Klotz on the Controversy Surrounding Screening for Prostate Cancer.
|
Oncology (Williston Park)
|
2016
|
0.75
|
|
92
|
The future of urologic oncology and surgeon-scientists: Proceedings of the World Urologic Oncology Federation, September 2007.
|
Urol Oncol
|
2009
|
0.75
|
|
93
|
Using consensus guidelines effectively.
|
Can Urol Assoc J
|
2010
|
0.75
|
|
94
|
Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment.
|
J Urol
|
2004
|
0.75
|
|
95
|
Active surveillance: current and future directions.
|
Curr Opin Urol
|
2013
|
0.75
|